Publications by authors named "Wayne Greaves"

Claim this Profile
F
Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen.
Chloe Orkin, John R Koethe, Princy N Kumar, Peter Sklar, Zhi Jin Xu, Wayne Greaves

Open Forum Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1 from a randomized trial.
Andrew Carr, Rosie Mngqibisa, Ilsiyar Khaertynova, Princy N Kumar, Shariq Haider, Wayne Greaves

AIDS· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials.
Sharon L Walmsley, Princy N Kumar, Chloe Orkin, Melanie Thompson, Kathleen Squires, Wayne Greaves

Open Forum Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes.
Amanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, Josep M Llibre, Bastian Neesgaard, Wayne Greaves

AIDS· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Princy Kumar, Margaret Johnson, Jean-Michel Molina, Giuliano Rizzardini, Pedro Cahn, Wayne Greaves

J Acquir Immune Defic Syndr· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate.
Wayne Greaves, Hong Wan, Ka Lai Yee, Bhargava Kandala, Pavan Vaddady

Antimicrob Agents Chemother· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Margaret Johnson, Princy Kumar, Jean-Michel Molina, Giuliano Rizzardini, Pedro Cahn, Wayne Greaves

J Acquir Immune Defic Syndr· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy.
Hala Shamsuddin, Casey L Raudenbush, Brittany L Sciba, Yun-Ping Zhou, T Christopher Mast, Wayne L Greaves

J Acquir Immune Defic Syndr· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.
Pedro Cahn, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Winai Ratanasuwan, Wayne Greaves

J Acquir Immune Defic Syndr· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.
K Rajender Reddy, David Roth, Annette Bruchfeld, Peggy Hwang, Barbara Haber, Wayne Greaves

Hepatol Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
Annette Bruchfeld, David Roth, Paul Martin, David R Nelson, Stanislas Pol, Wayne Greaves

Lancet Gastroenterol Hepatol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.
Kenneth E Sherman, Minhee Kang, Richard Sterling, Triin Umbleja, Kristen Marks, Wayne Greaves

World J Hepatol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
David Roth, David R Nelson, Annette Bruchfeld, AnnMarie Liapakis, Marcelo Silva, Wayne Greaves

Lancet· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Mark Sulkowski, Stanislas Pol, Josep Mallolas, Hugo Fainboim, Curtis Cooper, Wayne Greaves

Lancet Infect Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.
Marcos M Caseiro, Mark Nelson, Ricardo S Diaz, Joseph Gathe, Jose L de Andrade Neto, Wayne Greaves

J Infect· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
Paul McNicholas, Regis A Vilchez, Wayne Greaves, Sushma Kumar, Chinyere Onyebuchi

J Clin Virol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Opass Putcharoen, Sun Hee Lee, Timothy J Henrich, Zixin Hu, Jakapat Vanichanan, Wayne Greaves

J Virol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
Timothy J Wilkin, Zhaohui Su, Amy Krambrink, Jianmin Long, Wayne Greaves

J Acquir Immune Defic Syndr· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.
Paul McNicholas, Yi Wei, Jeannette Whitcomb, Wayne Greaves, Todd A Black

J Infect Dis· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).
Keith W Crawford, Chonghua Li, Anther Keung, Zhaohui Su, Michael D Hughes, Wayne Greaves

J Acquir Immune Defic Syndr· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
Zhaohui Su, Roy M Gulick, Amy Krambrink, Eoin Coakley, Michael D Hughes, Wayne L Greaves

J Infect Dis· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic and immunologic activity of PegIntron in HIV disease.
Jonathan B Angel, Wayne Greaves, Jianmin Long, Douglas Ward, Allan E Rodriguez

AIDS· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.
Noriaki Hosoya, Zhaohui Su, Timothy Wilkin, Roy M Gulick, Charles Flexner, Wayne L Greaves

J Clin Microbiol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.
Athe M N Tsibris, Bette Korber, Ramy Arnaout, Carsten Russ, Chien-Chi Lo, Wayne Greaves

PLoS One· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
Athe M N Tsibris, Roger Paredes, Amy Chadburn, Zhaohui Su, Timothy J Henrich, Wayne Greaves

Clin Infect Dis· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis